Oncogenic role and therapeutic target of leptin signaling in colorectal cancer

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 8, 2014, Pages 961-971

  Zhou, Weiqiang ^a   Tian, Yuwang ^b   Gong, Hangjun ^c   Guo, Shanchun ^b   Luo, Chengyu ^d  

^a SHENYANG MEDICAL COLLEGE   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Leptin; Leptin antagonist; Leptin signaling; Tumor angiogenesis

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEPTIN; LEPTIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; ANTINEOPLASTIC AGENT;

CANCER STEM CELL; CARCINOGENICITY; COLORECTAL CANCER; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; WNT SIGNALING PATHWAY; ANIMAL; COLORECTAL NEOPLASMS; COMPLICATION; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; OBESITY; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG DESIGN; HUMANS; LEPTIN; MOLECULAR TARGETED THERAPY; OBESITY; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84904411703     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.926889     Document Type: Review

References (157)

1. WHO. World Health Organization fact sheet for world wide prevalence of obesity. 2006. Available from: Www.who.int/mediacentre/factsheets/fs311/en/ index.html
2. Bibiloni MD, Pons A, Tur JA. Prevalence of overweight and obesity in adolescents: A systematic review. ISRN Obes 2013;2013:392747
3. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes 2013;2013:291546
4. Baskin ML, Ard J, Franklin F, Allison DB. Prevalence of obesity in the United States. Obes Rev 2005;6:5-7
5. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-55
6. Huxley R, Mendis S, Zheleznyakov E, et al. Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk-a review of the literature. Eur J Clin Nutr 2010;64:16-22
7. Cote AT, Harris KC, Panagiotopoulos C, et al. Childhood obesity and cardiovascular dysfunction. J Am Coll Cardiol 2013;62:1309-19
8. Kramer H, Dugas L, Shoham D. Obesity as an effect modifier of the risk of death in chronic kidney disease. Nephrol Dial Transplant 2013;28(Suppl 4):iv65-72
9. Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Endocrinol Metab Clin North Am 2008;37:623-33.viii
10. Kotsis V, Stabouli S, Papakatsika S, et al. Mechanisms of obesity-induced hypertension. Hypertens Res 2010;33:386-93
11. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: Old questions and new insights. Science 2011;332:1519-23
12. Travers ME, McCarthy MI. Type 2 diabetes and obesity: Genomics and the clinic. Hum Genet 2011;130:41-58
13. Basen-Engquist K, Chang M. Obesity and cancer risk: Recent review and evidence. Curr Oncol Rep 2011;13:71-6
14. Paz-Filho G, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci 2011;16:1634-50
15. Teucher B, Rohrmann S, Kaaks R. Obesity: Focus on all-cause mortality and cancer. Maturitas 2010;65:112-16
16. Wolin KY, Carson, K, Colditz GA. Obesity and cancer. Oncologist 2010;15:556-65
17. Colditz GA, Wolin KY, Gehlert S. Applying what we know to accelerate cancer prevention. Sci Transl Med 2012;4:124-127
18. Sundaram S, Johnson AR, Makowski L. Obesity, metabolism and the microenvironment: Links to cancer. J Carcinog 2013;12:19
19. Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, et al. Role of obesity-associated dysfunctional adipose tissue in cancer: A molecular nutrition approach. Biochim Biophys Acta 2011;1807:664-78
20. Zhang Y, Bellows CF, Kolonin MG. Adipose tissue-derived progenitor cells and cancer. World J Stem Cells 2010;2:103-13
21. Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009;148:43-66
22. Khan S, Shukla S, Sinha S, Meeran SM. Role of adipokines and cytokines in obesity-associated breast cancer: Therapeutic targets. Cytokine Growth Factor Rev 2013;24(6):503-13
23. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32 (Pubitemid 24365442)
24. Dehal A, Garrett T, Tedders SH, et al. Body mass index and death rate of colorectal cancer among a national cohort of U.S. adults. Nutr Cancer 2011;63:1218-25
25. Stattin P, Palmqvist R, Soderberg S, et al. Plasma leptin and colorectal cancer risk: A prospective study in Northern Sweden. Oncol Rep 2003;10:2015-21
26. Tamakoshi K, Toyoshima H, Wakai K, et al. Leptin is associated with an increased female colorectal cancer risk: A nested case-control study in Japan. Oncology 2005;68:454-61 (Pubitemid 41160977)
27. Chia VM, Newcomb PA, Lampe JW, et al. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2007;16:2697-703 (Pubitemid 351196326)
28. Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res 2010;70:5430-7
29. Healy LA, Howard JM, Ryan AM, et al. Metabolic syndrome and leptin are associated with adverse pathological features in male colorectal cancer patients. Colorectal Dis 2012;14:157-65
30. Liu L, Zhong R, Wei S, et al. The leptin gene family and colorectal cancer: Interaction with smoking behavior and family history of cancer. PLoS One 2013;8:e60777
31. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2006;207:12-22
32. Jarde T, Perrier S, Vasson MP, Caldefie-Chezet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 2011;47:33-43
33. Ray A, Cleary MP. Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 2010;14:443-51
34. Ribeiro R, Lopes C, Medeiros R. Leptin and prostate: Implications for cancer prevention-overview of genetics and molecular interactions. Eur J Cancer Prev 2004;13:359-68 (Pubitemid 39336599)
35. Wang SN, Lee KT, Ker CG. Leptin in hepatocellular carcinoma. World J Gastroenterol 2010;16:5801-9
36. Guo S, Liu M, Wang G, et al. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta 2012;1825:207-22
37. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:879-84 (Pubitemid 29427050)
38. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-6
39. Leinninger GM. Location, location, location: The CNS sites of leptin action dictate its regulation of homeostatic and hedonic pathways. Int J Obes (Lond) 2009;33(Suppl 2):S14-17
40. Myers MG Jr, Munzberg H, Leinninger GM, Leshan RL. The geometry of leptin action in the brain: More complicated than a simple ARC. Cell Metab 2009;9:117-23
41. Robertson SA, Leinninger GM, Myers MG Jr. Molecular and neural mediators of leptin action. Physiol Behav 2008;94:637-42 (Pubitemid 351847627)
42. Ashwin PJ, Dilipbhai PJ. Leptin and the cardiovascular system: A review. Recent Pat Cardiovasc Drug Discov 2007;2:100-9 (Pubitemid 46952441)
43. Imagawa K, Numata Y, Katsuura G, et al. Structure-function studies of human leptin. J Biol Chem 1998;273:35245-9 (Pubitemid 29028231)
44. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006;393:7-20 (Pubitemid 43049298)
45. Friedman J. Leptin, leptin receptors, and the control of body weight. In: Blum WF, Kiess W, Rascher W, editors. Leptin-the voice of adipose tissue. JA Barth Verlag; Heidelberg, Germany: 1997. p. 3-22
46. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995;83:1263-71 (Pubitemid 26007816)
47. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-8
48. Tartaglia LA. The leptin receptor. J Biol Chem 1997;272:6093-6 (Pubitemid 27118072)
49. Banks AS, Davis SM, Bates SH, Myers MG Jr. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000;275:14563-72 (Pubitemid 30339746)
50. Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997;272:32686-95 (Pubitemid 28011961)
51. Stahl N, Farruggella TJ, Boulton TG, et al. Choice of STATs and other substrates specified by modular tyrosinebased motifs in cytokine receptors. Science 1995;267:1349-53
52. Paik SS, Jang SM, Jang KS, et al. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol 2009;16:297-303
53. Kim HH, Kim YS, Kang YK, Moon JS. Leptin and peroxisome proliferatoractivated receptor gamma expression in colorectal adenoma. World J Gastroenterol 2012;18:557-62
54. Aloulou N, Bastuji-Garin S, Le Gouvello S, et al. Involvement of the leptin receptor in the immune response in intestinal cancer. Cancer Res 2008;68:9413-22
55. Slattery ML, Wolff RK. Leptin and colorectal cancer: An undefined link. Nat Clin Pract Gastroenterol Hepatol 2007;4:118-19 (Pubitemid 46416243)
56. Amemori S, Ootani A, Aoki S, et al. Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro. Am J Physiol Gastrointest Liver Physiol 2007;292:G923-9
57. Hardwick JC, Van Den Brink GR, Offerhaus GJ, et al. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 2001;121:79-90 (Pubitemid 32591517)
58. Aparicio T, Kotelevets L, Tsocas A, et al. Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc(Min/+) mice. Gut 2005;54:1136-45 (Pubitemid 41025909)
59. Hoda MR, Keely SJ, Bertelsen LS, et al. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg 2007;94:346-54 (Pubitemid 46423854)
60. Jaffe T, Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signaltransduction pathways. Int J Cancer 2008;123:2543-56
61. Liu Z, Uesaka T, Watanabe H, Kato N. High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin. Int J Oncol 2001;19:1009-14
62. Tessitore L, Vizio B, Jenkins O, et al. Leptin expression in colorectal and breast cancer patients. Int J Mol Med 2000;5:421-6
63. Bolukbas FF, Kilic H, Bolukbas C, et al. Serum leptin concentration and advanced gastrointestinal cancers: A case controlled study. BMC Cancer 2004;4:29
64. Stachowicz M, Mazurek U, Nowakowska-Zajdel E, et al. Leptin and its receptors in obese patients with colorectal cancer. J Biol Regul Homeost Agents 2010;24:287-95
65. Gialamas SP, Sergentanis TN, Antonopoulos CN, et al. Circulating leptin levels and risk of colorectal cancer and adenoma: A case-control study and meta-analysis. Cancer Causes Control 2013;24:2129-41
66. Aleksandrova K, Boeing H, Jenab M, et al. Leptin and soluble leptin receptor in risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Cancer Res 2012;72:5328-37
67. Ho GY, Wang T, Gunter MJ, et al. Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 2012;72:3029-37
68. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 2014;14:275-91
69. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11 (Pubitemid 33041634)
70. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68
71. Pang LY, Argyle DJ. Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochim Biophys Acta 2009;1792:380-91
72. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008;26:2813-20
73. Clarke MF. Self-renewal and solid-tumor stem cells. Biol Blood Marrow Transplant 2005;11:14-16 (Pubitemid 40186218)
74. Clevers H. The cancer stem cell: Premises, promises and challenges. Nat Med 2011;17:313-19
75. Bartucci M, Svensson S, Ricci-Vitiani L, et al. Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. Endocr Relat Cancer 2010;17:823-33
76. Feldman DE, Chen C, Punj V, et al. Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumorinitiating stem cells. Proc Natl Acad Sci USA 2012;109(3):829-34
77. Ogunwobi OO, Beales IL. The antiapoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis 2007;22:401-9 (Pubitemid 46336244)
78. Attoub S, Noe V, Pirola L, et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J 2000;14:2329-38
79. Wang D, Chen J, Chen H, et al. Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway. J Biosci 2012;37:91-101
80. Uchiyama T, Takahashi H, Sugiyama M, et al. Leptin receptor is involved in STAT3 activation in human colorectal adenoma. Cancer Sci 2011;102:367-72
81. Uchiyama T, Takahashi H, Endo H, et al. Role of the long form leptin receptor and of the STAT3 signaling pathway in colorectal cancer progression. Int J Oncol 2011;39:935-40
82. Rouet-Benzineb P, Aparicio T, Guilmeau S, et al. Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-kappaB signaling. J Biol Chem 2004;279:16495-502 (Pubitemid 38509348)
83. Abolhassani M, Aloulou N, Chaumette MT, et al. Leptin receptorrelated immune response in colorectal tumors: The role of colonocytes and interleukin-8. Cancer Res 2008;68:9423-32
84. Endo H, Hosono K, Uchiyama T, et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 2011;60:1363-71
85. Guo S, Gonzalez-Perez RR. Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PLoS One 2011;6(6):e21467
86. Knight BB, Oprea-Ilies GM, Nagalingam A, et al. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin induced migration of breast carcinoma cells. Endocr Relat Cancer 2011;18(4):413-28
87. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: Cell fate control and signal integration in development. Science 1999;284:770-6 (Pubitemid 29291335)
88. Leong KG, Karsan A. Recent insights into the role of notch signaling in tumorigenesis. Blood 2006;107:2223-33 (Pubitemid 43345539)
89. Radtke F, Raj K. The role of notch in tumorigenesis: Oncogene or tumour suppressor Nat Rev Cancer 2003;3:756-67 (Pubitemid 37328814)
90. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008;70:537-56 (Pubitemid 351738191)
91. de Sousa EM, Vermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res 2011;17:647-53
92. Bertrand FE, Angus CW, Partis WJ, Sigounas G. Developmental pathways in colon cancer: Crosstalk between WNT, BMP, hedgehog and notch. Cell Cycle 2012;11:4344-51
93. Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007;13:4042-5 (Pubitemid 47105963)
94. Fenton JI, Lavigne JA, Perkins SN, et al. Microarray analysis reveals that leptin induces autocrine/paracrine cascades to promote survival and proliferation of colon epithelial cells in an Apc genotypedependent fashion. Mol Carcinog 2008;47:9-21
95. Endo H, Hosono K, Uchiyama T, et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 2011;60(10):1363-71
96. Zheng Q, Dunlap SM, Zhu J, et al. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth and abrogates tumor initiating cell survival. Endocr Relat Cancer 2011;18(4):491-503
97. Gillespie C, Colbert L, McGlothen T, et al. DMBA-breast cancer in diet induced obesity (DIO) and lean mice is related to leptin signaling. In: CTRC-AACR San Antonio Breast Cancer Symposium; 6-10 December 2011; San Antonio, TX, USA
98. Steelman LS, Stadelman KM, Chappell WH, et al. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008;12:1139-65
99. Wickenden JA, Watson CJ. Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: A play in 3 Akts. Breast Cancer Res 2010;12:202
100. Agarwal E, Brattain MG, Chowdhury S. Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal 2013;25:1711-19
101. Sabbah M, Emami S, Redeuilh G, et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 2008;11:123-51
102. Huang XF, Chen JZ. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev 2009;10:610-16
103. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44 (Pubitemid 47123510)
104. Cheng SP, Yin PH, Hsu YC, et al. Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways. Oncol Rep 2011;26:1265-71
105. Uddin S, Bu R, Ahmed M, et al. Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma. Leuk Lymphoma 2010;51:1305-14
106. Uddin S, Bavi P, Siraj AK, et al. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocr Relat Cancer 2010;17:191-202
107. Riolfi M, Ferla R, Del Valle L, et al. Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol 2010;20:481-9
108. Uddin S, Bu R, Ahmed M, et al. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer 2009;8:74
109. Uddin S, Bavi PP, Hussain AR, et al. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis 2009;30:1832-40
110. Shen Y, Wang Q, Zhao Q, Zhou J. Leptin promotes the immune escape of lung cancer by inducing proinflammatory cytokines and resistance to apoptosis. Mol Med Report 2009;2:295-9
111. Gao J, Tian J, Lv Y, et al. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci 2009;100:389-95
112. Miyazaki T, Bub JD, Iwamoto Y. c-Jun NH(2)-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt. Biochim Biophys Acta 2008;1782:593-604
113. Saxena NK, Sharma D, Ding X, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007;67:2497-507 (Pubitemid 46548934)
114. Gonzalez-Perez RR, Xu Y, Guo S, et al. Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal 2010;22:1350-62
115. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132:344-62
116. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: How intimate is this relationship. Mol Cell Biochem 2010;336:25-37
117. Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009;6:327-34
118. Zhou W, Guo S, Gonzalez-Perez RR. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer 2011;104:128-37
119. Mattace Raso G, Esposito E, Iacono A, et al. Leptin induces nitric oxide synthase type II in C6 glioma cells. Role for nuclear factor-kappaB in hormone effect. Neurosci Lett 2006;396:121-6 (Pubitemid 43276425)
120. Yeh WL, Lu DY, Lee MJ, Fu WM. Leptin induces migration and invasion of glioma cells through MMP-13 production. Glia 2009;57:454-64
121. Yang SN, Chen HT, Tsou HK, et al. Leptin enhances cell migration in human chondrosarcoma cells through OBRl leptin receptor. Carcinogenesis 2009;30:566-74
122. Huang CY, Yu HS, Lai TY, et al. Leptin increases motility and integrin upregulation in human prostate cancer cells. J Cell Physiol 2011;226:1274-82
123. Ogunwobi OO, Beales IL. Cyclo-oxygenase-independent inhibition of apoptosis and stimulation of proliferation by leptin in human colon cancer cells. Dig Dis Sci 2007;52:1934-45 (Pubitemid 47024680)
124. Gonzalez RR, Cherfils S, Escobar M, et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem 2006;281:26320-8 (Pubitemid 44401840)
125. Rene Gonzalez R, Watters A, Xu Y, et al. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res 2009;11:R36
126. Fletcher S, Drewry JA, Shahani VM, et al. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol 2009;87:825-33
127. Masciocchi D, Gelain A, Villa S, et al. Signal transducer and activator of transcription 3 (STAT3): A promising target for anticancer therapy. Future Med Chem 2011;3:567-97
128. Mankan AK, Greten FR. Inhibiting signal transducer and activator of transcription 3: Rationality and rationale design of inhibitors. Expert Opin Investig Drugs 2011;20:1263-75
129. Zhao M, Jiang B, Gao FH. Small molecule inhibitors of STAT3 for cancer therapy. Curr Med Chem 2011;18(26):4012-18
130. Bates SH, Kulkarni RN, Seifert M, Myers MG Jr. Roles for leptin receptor/STAT3-dependent and-independent signals in the regulation of glucose homeostasis. Cell Metab 2005;1:169-78 (Pubitemid 43960601)
131. Ratke J, Entschladen F, Niggemann B, et al. Leptin stimulates the migration of colon carcinoma cells by multiple signaling pathways. Endocr Relat Cancer 2010;17:179-89
132. Catalano S, Giordano C, Rizza P, et al. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. J Cell Physiol 2009;218:490-500
133. Li L, Gao Y, Zhang LL, He DL. Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol Ther 2008;7:1787-92
134. Saxena NK, Vertino PM, Anania FA, Sharma D. Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem 2007;282:13316-25 (Pubitemid 47100545)
135. Pai R, Lin C, Tran T, Tarnawski A. Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. Biochem Biophys Res Commun 2005;331:984-92 (Pubitemid 40692458)
136. Yin N, Wang D, Zhang H, et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res 2004;64:5870-5 (Pubitemid 39095588)
137. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, et al. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2002;293:622-8 (Pubitemid 34694255)
138. Russo VC, Metaxas S, Kobayashi K, et al. Antiapoptotic effects of leptin in human neuroblastoma cells. Endocrinology 2004;145:4103-12 (Pubitemid 39120558)
139. Cascio S, Ferla R, D'Andrea A, et al. Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells. J Cell Physiol 2009;221:189-94
140. Ren H, Zhao T, Wang X, et al. Leptin upregulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2010;394:59-63
141. Jiang H, Yu J, Guo H, et al. Upregulation of survivin by leptin/STAT3 signaling in MCF-7 cells. Biochem Biophys Res Commun 2008;368:1-5
142. Ohba S, Lanigan TM, Roessler BJ. Leptin receptor JAK2/STAT3 signaling modulates expression of frizzled receptors in articular chondrocytes. Osteoarthritis Cartilage 2010;18:1620-9
143. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006;70:1469-80
144. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006;59:15-26 (Pubitemid 43903276)
145. Li Y, Ye D. Cancer therapy by targeting hypoxia-inducible factor-1. Curr Cancer Drug Targets 2010;10(7):782-9
146. Li Z, Rich JN. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol 2010;345:21-30
147. Grosfeld A, Andre J, Hauguel-De Mouzon S, et al. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem 2002;277:42953-7 (Pubitemid 35285673)
148. Wu MH, Chen KF, Lin SC, et al. Aberrant expression of leptin in human endometriotic stromal cells is induced by elevated levels of hypoxia inducible factor-1alpha. Am J Pathol 2007;170:590-8
149. Koda M, Sulkowska M, Kanczuga-Koda L, et al. Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 alpha in human colorectal cancer. Ann Oncol 2007;18(Suppl 6):vi116-19
150. Gonzalez RR, Leavis PC. A peptide derived from the human leptin molecule is a potent inhibitor of the leptin receptor function in rabbit endometrial cells. Endocrine 2003;21:185-95 (Pubitemid 36936361)
151. Otvos L Jr, Kovalszky I, Riolfi M, et al. Efficacy of a leptin receptor antagonist peptide in a mouse model of triplenegative breast cancer. Eur J Cancer 2011;47:1578-84
152. Beccari S, Kovalszky I, Wade JD, et al. Designer peptide antagonist of the leptin receptor with peripheral antineoplastic activity. Peptides 2013;44:127-34
153. Lee CW, Raskett CM, Prudovsky I, Altieri DC. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res 2008;68:5273-81
154. Lee CW, Simin K, Liu Q, et al. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res 2008;10:R97
155. Zabeau L, Verhee A, Catteeuw D, et al. Selection of non-competitive leptin antagonists using a random nanobodybased approach. Biochem J 2012;441:425-34
156. Fazeli M, Zarkesh-Esfahani H, Wu Z, et al. Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. J Immunol Methods 2006;312:190-200 (Pubitemid 44209011)
157. Carpenter B, Hemsworth GR, Wu Z, et al. Structure of the human obesity receptor leptin-binding domain reveals the mechanism of leptin antagonism by a monoclonal antibody. Structure 2012;20:87-497